STOCK TITAN
  1. Home
  2. News
  3. KPTI

Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.

Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.

Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.

For more information, please visit www.karyopharm.com.

News

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced long-term follow-up data from the Phase 1 study of Selinexor in combination with Ruxolitinib in treatment-naïve Myelofibrosis, suggesting disease modification and reinforcing the potential for this combination to become a novel, first-line treatment for JAKi-Naïve patients with MF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
clinical trial
-
News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) granted 15,700 restricted stock units (RSUs) to three newly-hired employees as part of the Company's 2022 Inducement Stock Incentive Plan. The RSU awards will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting is subject to the employee's continued service, and the RSU award will be immediately exercisable in full in the event of a 'change in control event' and certain termination conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.62%
Tags
none
-
News

Karyopharm to Participate at Upcoming Investor Conferences

Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announces senior management participation in investor conferences in November, including Jefferies 2023 London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts and slides available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.6%
Tags
conferences
News

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

Rhea-AI Summary
Karyopharm Therapeutics Inc. announced updated long-term safety and efficacy data from the SIENDO study, showing promising results in patients with TP53 wild-type endometrial cancer. The exploratory subgroup analysis demonstrated an encouraging overall survival (OS) signal, with a hazard ratio of 0.76 and median OS not reached after a median follow-up of 28.9 months. Selinexor, the investigational therapy, showed potential as a foundational treatment for patients with TP53 wild-type endometrial cancer. No new safety signals were identified, and the most common adverse events were manageable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
News

Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

Rhea-AI Summary
Karyopharm Therapeutics Inc. announced that selinexor data in myelofibrosis will be presented at the 65th ASH Annual Meeting. The data include long-term efficacy results from a Phase 1 study of selinexor in combination with ruxolitinib. The company aims to improve long-term outcomes for patients with this disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
none
-
News

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary
Karyopharm Therapeutics Inc. reported third-quarter 2023 total revenue of $36.0 million and U.S. XPOVIO® net product revenue of $30.2 million. The company maintains its full-year 2023 total revenue guidance of $145 million to $160 million, including U.S. XPOVIO net product revenue guidance of $110 million to $125 million. Key highlights include strong SVR and TSS durability observed in a Phase 1 study of selinexor and ruxolitinib in JAK inhibitor-naïve myelofibrosis patients, and a clinical trial collaboration with Bristol Myers Squibb to evaluate a novel CELMoD agent in combination with selinexor in patients with R/R multiple myeloma progressing after T-cell immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
earnings
News

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Rhea-AI Summary
Karyopharm Therapeutics has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the combination of mezigdomide and selinexor in patients with relapsed/refractory multiple myeloma. The trial will assess the combination in patients who have prior exposure to certain drug agents and have received at least two prior lines of therapy. The trial is expected to be initiated in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
-
News

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023

Rhea-AI Summary
Karyopharm Therapeutics Inc. will report Q3 2023 financial results on November 2, 2023. Conference call and webcast to discuss the results and company updates will be held at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences earnings
-
News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Karyopharm Therapeutics grants 83,850 RSUs to new employees, vesting over 3 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
News

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

Rhea-AI Summary
Karyopharm Therapeutics announces presentation of new selinexor data at international conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.08%
Tags
conferences

FAQ

What is the current stock price of Karyopharm Therapeutics (KPTI)?

The current stock price of Karyopharm Therapeutics (KPTI) is $0.6664 as of January 22, 2025.

What is the market cap of Karyopharm Therapeutics (KPTI)?

The market cap of Karyopharm Therapeutics (KPTI) is approximately 88.3M.

What is Karyopharm Therapeutics' main focus?

Karyopharm Therapeutics specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other major diseases.

What is XPOVIO® (selinexor)?

XPOVIO® is a first-in-class, oral exportin 1 (XPO1) inhibitor approved for the treatment of multiple oncology indications, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL).

What recent achievements has Karyopharm reported?

Karyopharm recently announced promising long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib for myelofibrosis. The company also reported strong financial performance with total revenue of $146.0 million for the year 2023.

Who are Karyopharm's global partners?

Karyopharm has partnered with Antengene, Menarini, Neopharm, and FORUS to market XPOVIO in international markets, including Europe, China, South Korea, and Israel.

What are Karyopharm's financial highlights?

For Q4 2023, Karyopharm reported total revenue of $33.7 million and a full-year revenue of $146.0 million. The company had a cash position of $192.4 million as of December 31, 2023.

What are the key indications for XPOVIO?

XPOVIO is approved for use in combination with Velcade and dexamethasone for multiple myeloma, in combination with dexamethasone for heavily pre-treated multiple myeloma, and as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

What is the significance of Karyopharm's research on nuclear export proteins?

Karyopharm's research targets nuclear export dysregulation, a fundamental mechanism of oncogenesis, aiming to develop therapies that inhibit this process and treat various cancers effectively.

How does Karyopharm support clinical trials and research?

Karyopharm is engaged in several mid- and late-stage clinical trials across multiple high unmet need cancer indications, including endometrial cancer and myelofibrosis. The company also collaborates with global partners and research institutions to advance its pipeline.

What are the safety considerations for XPOVIO?

Common treatment-emergent adverse events for XPOVIO include nausea, vomiting, diarrhea, and neutropenia. Patients are advised not to breastfeed during treatment. Full prescribing information is available on www.XPOVIO.com.

How can I get more information about Karyopharm's products or clinical trials?

For more information, you can contact Karyopharm's Medical Information department at +1 (888) 209-9326 or via email at medicalinformation@karyopharm.com.
Stock KPTI logo
Karyopharm Therapeutics Inc.

Nasdaq:KPTI

KPTI Rankings

#4536 Ranked by Market Cap
N/A Ranked by Dividends

KPTI Stock Data

88.33M
118.36M
6.21%
48.24%
15.68%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON